These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

360 related items for PubMed ID: 25781911

  • 1. The Serotonin 2C Receptor Agonist Lorcaserin Attenuates Intracranial Self-Stimulation and Blocks the Reward-Enhancing Effects of Nicotine.
    Zeeb FD, Higgins GA, Fletcher PJ.
    ACS Chem Neurosci; 2015 Jul 15; 6(7):1231-40. PubMed ID: 25781911
    [Abstract] [Full Text] [Related]

  • 2. Lorcaserin, a 5-HT2C agonist, decreases nicotine self-administration in female rats.
    Levin ED, Johnson JE, Slade S, Wells C, Cauley M, Petro A, Rose JE.
    J Pharmacol Exp Ther; 2011 Sep 15; 338(3):890-6. PubMed ID: 21636655
    [Abstract] [Full Text] [Related]

  • 3. Lorcaserin Suppresses Oxycodone Self-Administration and Relapse Vulnerability in Rats.
    Neelakantan H, Holliday ED, Fox RG, Stutz SJ, Comer SD, Haney M, Anastasio NC, Moeller FG, Cunningham KA.
    ACS Chem Neurosci; 2017 May 17; 8(5):1065-1073. PubMed ID: 28107783
    [Abstract] [Full Text] [Related]

  • 4. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization.
    Thomsen WJ, Grottick AJ, Menzaghi F, Reyes-Saldana H, Espitia S, Yuskin D, Whelan K, Martin M, Morgan M, Chen W, Al-Shamma H, Smith B, Chalmers D, Behan D.
    J Pharmacol Exp Ther; 2008 May 17; 325(2):577-87. PubMed ID: 18252809
    [Abstract] [Full Text] [Related]

  • 5. Varenicline attenuates nicotine-enhanced brain-stimulation reward by activation of alpha4beta2 nicotinic receptors in rats.
    Spiller K, Xi ZX, Li X, Ashby CR, Callahan PM, Tehim A, Gardner EL.
    Neuropharmacology; 2009 Jul 17; 57(1):60-6. PubMed ID: 19393252
    [Abstract] [Full Text] [Related]

  • 6. Directly Observable Behavioral Effects of Lorcaserin in Rats.
    Serafine KM, Rice KC, France CP.
    J Pharmacol Exp Ther; 2015 Dec 17; 355(3):381-5. PubMed ID: 26384326
    [Abstract] [Full Text] [Related]

  • 7. The 5-HT2C receptor agonist lorcaserin reduces nicotine self-administration, discrimination, and reinstatement: relationship to feeding behavior and impulse control.
    Higgins GA, Silenieks LB, Rossmann A, Rizos Z, Noble K, Soko AD, Fletcher PJ.
    Neuropsychopharmacology; 2012 Apr 17; 37(5):1177-91. PubMed ID: 22189292
    [Abstract] [Full Text] [Related]

  • 8. Effects of the serotonin 5-HT2A and 5-HT2C receptor ligands on the discriminative stimulus effects of nicotine in rats.
    Zaniewska M, McCreary AC, Przegaliński E, Filip M.
    Eur J Pharmacol; 2007 Oct 01; 571(2-3):156-65. PubMed ID: 17617403
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of chemically diverse 5-HT₂c receptor agonists on behaviours motivated by food and nicotine and on side effect profiles.
    Higgins GA, Silenieks LB, Lau W, de Lannoy IA, Lee DK, Izhakova J, Coen K, Le AD, Fletcher PJ.
    Psychopharmacology (Berl); 2013 Apr 01; 226(3):475-90. PubMed ID: 23184281
    [Abstract] [Full Text] [Related]

  • 10. Activation of 5-HT(2C) receptors reduces the locomotor and rewarding effects of nicotine.
    Grottick AJ, Corrigall WA, Higgins GA.
    Psychopharmacology (Berl); 2001 Sep 01; 157(3):292-8. PubMed ID: 11605085
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of Cocaine and 3,4-Methylenedioxypyrovalerone (MDPV) Self-Administration by Lorcaserin Is Mediated by 5-HT2C Receptors in Rats.
    Gannon BM, Sulima A, Rice KC, Collins GT.
    J Pharmacol Exp Ther; 2018 Mar 01; 364(2):359-366. PubMed ID: 29217539
    [Abstract] [Full Text] [Related]

  • 12. Effects of the 5-HT2C receptor agonist Ro60-0175 and the 5-HT2A receptor antagonist M100907 on nicotine self-administration and reinstatement.
    Fletcher PJ, Rizos Z, Noble K, Soko AD, Silenieks LB, Lê AD, Higgins GA.
    Neuropharmacology; 2012 Jun 01; 62(7):2288-98. PubMed ID: 22342986
    [Abstract] [Full Text] [Related]

  • 13. Differential effects of 5-HT2C receptor activation by WAY 161503 on nicotine-induced place conditioning and locomotor activity in rats.
    Hayes DJ, Mosher TM, Greenshaw AJ.
    Behav Brain Res; 2009 Feb 11; 197(2):323-30. PubMed ID: 18805442
    [Abstract] [Full Text] [Related]

  • 14. Differential effects of serotonin (5-HT)2 receptor-targeting ligands on locomotor responses to nicotine-repeated treatment.
    Zaniewska M, McCreary AC, Wydra K, Filip M.
    Synapse; 2010 Jul 11; 64(7):511-9. PubMed ID: 20196140
    [Abstract] [Full Text] [Related]

  • 15. Effects of lorcaserin (Belviq®) on nicotine- and food-maintained responding in non-human primates.
    Jacobs DS, Barkin CE, Kohut MR, Bergman J, Kohut SJ.
    Drug Alcohol Depend; 2017 Dec 01; 181():94-101. PubMed ID: 29040827
    [Abstract] [Full Text] [Related]

  • 16. Preclinical Abuse Potential Assessment of Flibanserin: Effects on Intracranial Self-Stimulation in Female and Male Rats.
    Lazenka MF, Blough BE, Negus SS.
    J Sex Med; 2016 Mar 01; 13(3):338-49. PubMed ID: 26831817
    [Abstract] [Full Text] [Related]

  • 17. Preclinical evidence for combining the 5-HT2C receptor agonist lorcaserin and varenicline as a treatment for nicotine dependence.
    Fletcher PJ, Li Z, Silenieks LB, MacMillan C, DeLannoy I, Higgins GA.
    Addict Biol; 2019 May 01; 24(3):376-387. PubMed ID: 29498158
    [Abstract] [Full Text] [Related]

  • 18. Cannabidiol inhibits the reward-facilitating effect of morphine: involvement of 5-HT1A receptors in the dorsal raphe nucleus.
    Katsidoni V, Anagnostou I, Panagis G.
    Addict Biol; 2013 Mar 01; 18(2):286-96. PubMed ID: 22862835
    [Abstract] [Full Text] [Related]

  • 19. Characterization of the discriminative stimulus effects of lorcaserin in rats.
    Serafine KM, Rice KC, France CP.
    J Exp Anal Behav; 2016 Sep 01; 106(2):107-16. PubMed ID: 27640338
    [Abstract] [Full Text] [Related]

  • 20. Persistent attenuation of nicotine self-administration in rats by co-administration of chronic nicotine infusion with the dopamine D1 receptor antagonist SCH-23390 or the serotonin 5-HT2C agonist lorcaserin.
    DiPalma D, Rezvani AH, Willette B, Wells C, Slade S, Hall BJ, Levin ED.
    Pharmacol Biochem Behav; 2019 Jan 01; 176():16-22. PubMed ID: 30419272
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.